Analysis of epidemiological and molecular data from invasive meningococcal disease surveillance in the Czech Republic, 1993–2020

Česká verze

Authors: P. Křížová ¹ ; M. Honskus ^1,2 ; Z. Okonji ¹; M. Musílek ¹; J. Kozáková ¹
Authors place of work: Národní referenční laboratoř pro meningokokové nákazy, Centrum epidemiologie a mikrobiologie, Státní zdravotní ústav, Praha ¹; 3. lékařská fakulta Univerzity Karlovy, Praha ²
Published in the journal: Epidemiol. Mikrobiol. Imunol. 71, 2022, č. 3, s. 148-160
Category: Původní práce

Summary

Aim: An analysis is presented of epidemiological and molecular data from invasive meningococcal disease (IMD) surveillance in the Czech Republic (CR) for 1993–2020, comparing trends in four seven-year periods: 1993–1999, 2000–2006, 2007–2013, and 2014–2020.

Material and Methods: IMD surveillance data are generated by linking National Reference Laboratory for Meningococcal Diseases data and epidemiological data routinely reported to the infectious diseases information systems, with duplicate data removal. Whole genome sequencing (WGS) was used for analysis of selected isolates from IMD cases. In this study, WGS data are analysed on 323 isolates recovered from IMD cases in the Czech Republic between 1993–2020.

Results: Over the entire study period 1993–2020, 2,674 cases were recorded in the IMD surveillance programme, of which 272 were fatal. In the first seven-year period, the highest incidence rate of 2.2/100,000 population was reported in 1995, a gradual decline from 0.8 to 0.6/100,000 was observed in the third period, and in the last period, this decline continued until 2020, achieving a low of 0.2/100,000. In all four study periods, the age group 0-11 months was the most affected, followed by 1–4-year-olds and 15-19-year-olds. Serogroup B caused the highest number of cases (43.6%), followed by serogroups C (34.9%), Y (1.8%), and W (1.5%). Serogroup X was only found in three cases. The overall case fatality rate in the entire study period was 10.2%, with no decline seen in the four periods. The highest case fatality rate was associated with serogroup Y (14.6%), followed by serogroups W (12.5%), C (12.0%), and B (8.1%). In terms of age, the highest case fatality rate was observed in people aged 65+ (24.7%).

The WGS data for 323 IMD isolates from 1993-2020 showed the highest representation of eight clonal complexes: cc11, cc44/41, cc32, cc267, cc23, cc18, cc35, and cc865. Isolates of serogroup C, cc11, from the last study period form two genetically distinct populations with distinct phenotypes that are genetically distant from the lineage of cc11 isolates from the first two periods. The study population included a unique Czech subpopulation of serogroup W isolates (ST-3342, cc865), recorded only in the last two periods (2007–2020), whose position in the phylogenetic network supports the theory that the serogroup W population in the Czech Republic originated from serogroup B isolates as a result of serogroup switch (capsule switch). Clonal complexes cc41/44, cc32, cc267, cc18, and cc35 are predominantly composed of serogroup B isolates, while cc23 includes exclusively serogroup Y isolates.

Conclusions: The analysis of surveillance data over a 28-year period confirms that the vaccination strategy currently used in the Czech Republic, i.e., vaccination of young children and adolescents with a combination of MenB vaccine and quadrivalent conjugate ACWY vaccine, appears to be the most appropriate in the context of the long-term epidemiological situation of IMD in the CR.

Keywords:

surveillance – Neisseria meningitidis – invasive meningococcal disease – whole genome sequencing (WGS) – case fatality rate – serogroup

Zdroje

1. Parikh SR, Campbell H, Bettinger JA, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect, 2020; 81(4):483–498. DOI: 10.1016/j.jinf.2020.05.079. PMID: 32504737.

2. Whitaker R, Gomes Dias J, Ramliden M, et al. The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004– 2014. Vaccine, 2017; 35(16):2034–2041. DOI: 10.1016/j.vaccine. 2017.03.007. PMID: 28314560.

3. European Centre for Disease Prevention and Control. Invasive meningococcal disease. In: ECDC. Annual epidemiological report for 2017. Stockholm: ECDC; 2019.

4. Křížová P, Rožnovský L. Meningokokové onemocnění. MAXDORF 2011, ISBN 978-80-7345-239-1.

5. Česká vakcinologická společnost ČLS JEP. Doporučení a stanoviska [online]. 2022. Dostupné na www: https://www.vakcinace. eu/doporuceni-a-stanoviska

6. Národní referenční laboratoř pro meningokokové nákazy. Očkování proti meningokokovým onemocněním [online]. Dostupné na www: www.szu.cz/ockovani-proti-meningokokovym-onemocnenim

7. Vyhláška MZ č. 473/2008 Sb. Vyhláška o systému epidemiologické bdělosti pro vybrané infekce [online]. Dostupné na www:<www.zakonyprolidi.cz/cs/2008-473>

8. EUR-Lex. Access to European Union law [online]. 2018. Dostupné na www: 9. Český statistický úřad. Věkové složení obyvatelstva [online]. Dostupné na www: <https://eur-lex.europa.eu/legal-content/CS/TXT/?qid=1551343581293&uri=CELEX:32018D0945>

9. Český statistický úřad. Věkové složení obyvatelstva [online]. Dostupné na www: <https://www.czso.cz

10. Národní referenční laboratoř pro meningokokové nákazy. Vybrané publikace [online]. Dostupné na www: http://www.szu.cz/nrl-pro-meningokokove-nakazy-publikace

11. PubMLST database: Public databases for molecular typing and microbial genome diversity. Dostupné na www: <https://pubmlst.org/organisms/neisseria-spp/>

12. Honskus M, Okonji Z, Musílek M, et al. Detailed molecular characterization of Neisseria meningitidis isolates by whole genome sequencing (WGS), Czech Republic, 2010–2019. Epidemiol Mikrobiol Imunol, 2021; 70(3):168–177. PMID: 34641691.

13. Ladhani SN, Beebeejaun K, Lucidarme J, et al. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis. 2015; 60(4):578–585. DOI: 10.1093/cid/ ciu881. PMID: 25389259.

14. Törös B, Hedberg ST, Jacobsson S, et al. Surveillance of invasive Neisseria meningitidis with a serogroup Y update, Sweden 2010 to 2012. Euro Surveill. 2014; 19(42):20940. DOI: 10.2807/1560- 7917.es2014.19.42.20940. PMID: 25358044.

15. Bröker M, Emonet S, Fazio C, et al. Meningococcal serogroup Y disease in Europe: Continuation of high importance in some European regions in 2013. Hum Vaccin Immunother. 2015; 11(9):2281-6. DOI: 10.1080/21645515.2015.1051276. PMID: 26036710.

16. Caugant DA. Genetics and evolution of Neisseria meningitidis: importance for the epidemiology of meningococcal disease. Infect Genet Evol. 2008; 8(5):558–565. DOI: 10.1016/j.meegid. 2008.04.002. PMID: 18479979.

17. Watkins ER, Maiden MC. Persistence of hyperinvasive meningococcal strain types during global spread as recorded in the PubMLST database. PLoS One. 2012; 7(9):e45349. DOI: 10.1371/ journal.pone.0045349. PMID: 23028953.

18. Lucidarme J, Hill DM, Bratcher HB, et al. Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage. J Infect. 2015; 71(5):544- 552. DOI: 10.1016/j.jinf.2015.07.007. PMID: 26226598.

19. Brehony C, Jolley KA, Maiden MC. Multilocus sequence typing for global surveillance of meningococcal disease. FEMS Microbiol Rev. 2007; 31(1):15–26. DOI: 10.1111/j.1574-6976.2006.00056.x. PMID: 17168997.

20. Bratcher HB, Brehony C, Heuberger S, et al. Establishment of the European meningococcal strain collection genome library (EMSC-GL) for the 2011 to 2012 epidemiological year. Euro Surveill. 2018; 23(20):17-00474. DOI: 10.2807/1560-7917. ES.2018.23.20.17-00474. PMID: 29790460.

21. Rodgers E, Bentley SD, Borrow R, et al. The global meningitis genome partnership. J Infect. 2020; 81(4):510–520. DOI: 10.1016/j. jinf.2020.06.064. PMID: 32615197.

22. Lucidarme J, Scott KJ, Ure R, et al. An international invasive meningococcal disease outbreak due to a novel and rapidly expanding serogroup W strain, Scotland and Sweden, July to August 2015. Euro Surveill. 2016; 21(45):30395. DOI: 10.2807/1560-7917. ES.2016.21.45.30395. PMID: 27918265.

23. Honskus M, Okonji Z, Musílek M, et al. Whole genome sequencing of Neisseria meningitidis W isolates from the Czech Republic recovered in 1984-2017. PLoS One. 2018; 13(9):e0199652. DOI: 10.1371/journal.pone.0199652. PMID: 30212468.

24. Tzeng YL, Thomas J, Stephens DS. Regulation of capsule in Neisseria meningitidis. Crit Rev Microbiol. 2016; 42(5):759-772. DOI: 10.3109/1040841X.2015.1022507. PMID: 26089023.

25. Brueggemann AB, Jansen van Rensburg MJ, Shaw D, et al. Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. Lancet Digit Health. 2021; 3(6):e360-e370. DOI: 10.1016/S2589-7500(21)00077-7. PMID: 34045002.

26. Alderson MR, Arkwright PD, Bai X, et al. Surveillance and control of meningococcal disease in the COVID-19 era: A Global Meningococcal Initiative review. J Infect. 2022; 84(3):289-296. DOI: 10.1016/j.jinf.2021.11.016. PMID: 34838594.

27. Taha MK, Deghmane AE. Impact of COVID-19 pandemic and the lockdown on invasive meningococcal disease. BMC Res Notes. 2020; 13(1):399. DOI: 10.1186/s13104-020-05241-9. PMID: 32854773.

28. Subbarao S, Campbell H, Ribeiro S, et al. Invasive Meningococcal Disease, 2011-2020, and Impact of the COVID-19 Pandemic, England. Emerg Infect Dis. 2021; 27(9):2495-2497. DOI: 10.3201/ eid2709.204866. PMID: 34193335.

29. Clark SA, Campbell H, Mensah AA, et al. An increase in group B invasive meningococcal disease among adolescents and young adults in England following easing of COVID-19 containment measures [Preprint]. Dostupné na www: <https://ssrn.com/abstract=3998164>